Last updated: September 8, 2026
IPI-549, also known as eganelisib, is an oral, selective phosphoinositide 3-kinase gamma, or PI3K-gamma, inhibitor developed by Infinity Pharmaceuticals for combination treatment in advanced solid tumors. Its clinical program has largely stalled after mixed results in the MARIO-3 study. IPI-549 has no FDA approval, no Orange Book listing, no commercial revenue, and no established generic or biosimilar entry pathway. Its near-term commercial value is therefore dependent on a third-party rescue, a new oncology combination strategy, or an out-licensing transaction.
What is IPI-549 and how does eganelisib work?
IPI-549 is designed to inhibit PI3K-gamma, an enzyme associated with immunosuppressive myeloid cells in the tumor microenvironment. The development thesis was that blocking PI3K-gamma could reprogram tumor-associated macrophages and improve the activity of immune checkpoint inhibitors such as nivolumab and atezolizumab.
The candidate was evaluated primarily in:
- Triple-negative breast cancer, or TNBC
- Renal cell carcinoma, or RCC
- Other advanced solid tumors
- Combination regimens involving checkpoint inhibitors and chemotherapy
IPI-549 is distinct from approved PI3K inhibitors such as alpelisib, idelalisib, duvelisib and inavolisib. Those products primarily target PI3K alpha, delta or broader pathway activity. IPI-549 was developed as a PI3K-gamma-selective immuno-oncology agent.
What is the current development status of IPI-549?
IPI-549 is not an approved medicine and does not have an active late-stage registration program publicly supporting a near-term launch.
Infinity’s central clinical program was the MARIO platform. MARIO-1 generated early evidence of clinical activity for IPI-549 in combination with nivolumab. The company then advanced MARIO-3, a randomized Phase 2 study testing IPI-549 in combination with atezolizumab and nab-paclitaxel in first-line metastatic TNBC, with an additional RCC cohort.
The development sequence is summarized below.
| Period |
Development event |
Commercial relevance |
| 2017-2019 |
Early clinical development and partnering activity |
Established IPI-549 as a clinical-stage PI3K-gamma program |
| 2020 |
FDA Fast Track designation reported for an IPI-549 combination program |
Regulatory interaction accelerated, but did not establish approval eligibility |
| 2020-2021 |
MARIO-3 Phase 2 enrollment and early readouts |
Early response data supported continued investigation |
| 2021-2022 |
MARIO-3 data failed to establish a clear registrational path |
Reduced probability of near-term approval |
| 2022 onward |
Clinical development deprioritized or discontinued in the disclosed program |
No public launch timeline or active pivotal program |
| Through 2024 |
No NDA, BLA, approval or commercial launch reported |
Revenue remains zero |
Early MARIO-3 results indicated high response rates in treatment-naive TNBC, but subsequent development did not produce a sufficiently differentiated or durable clinical profile to support continued investment at the original scale. Infinity’s public disclosures indicated that the program was no longer being advanced as a primary clinical asset.
What were the MARIO-1 and MARIO-3 results?
MARIO-1 was an open-label Phase 1/2 study evaluating IPI-549 alone and in combination with nivolumab. The program generated evidence that IPI-549 could be administered with checkpoint blockade and showed signals of activity in selected tumor types.
MARIO-3 evaluated IPI-549 with atezolizumab and nab-paclitaxel in first-line metastatic TNBC. Publicly reported interim data showed a high objective response rate, but the durability and comparative benefit were not sufficient to create a clear path toward regulatory approval.
The principal development risks were:
- Lack of a confirmed survival advantage.
- Dependence on a complex triplet regimen.
- Competition from antibody-drug conjugates and other immuno-oncology combinations.
- Limited validation of PI3K-gamma inhibition as a broadly effective mechanism.
- Clinical development cost relative to the size of the addressable niche.
The program also faced the standard risk for tumor-microenvironment therapies: biomarker selection. Without a validated diagnostic identifying tumors dependent on PI3K-gamma-mediated immune suppression, clinical response rates may not translate across broad solid-tumor populations.
What is the FDA regulatory status of IPI-549?
IPI-549 has not received FDA approval. The FDA has not approved eganelisib for TNBC, RCC, melanoma, colorectal cancer or any other indication.
| FDA status item |
IPI-549 position |
| FDA approval |
None |
| NDA or BLA approval |
None publicly reported |
| Fast Track designation |
Reported during development |
| Breakthrough Therapy designation |
No publicly confirmed designation |
| Priority Review |
None |
| FDA label |
None |
| REMS |
None |
| Orange Book listing |
None |
| Approved indication |
None |
Fast Track designation does not confer approval, exclusivity or a guaranteed review outcome. If development resumes, the sponsor would likely need a new clinical strategy and a trial capable of demonstrating clinically meaningful benefit against current standards of care.
What patents protect IPI-549 and when could exclusivity expire?
IPI-549 is protected by composition-of-matter, pharmaceutical composition and method-of-use patent families associated with PI3K-gamma inhibition. Public corporate filings describe patent protection as extending into the early 2030s for certain rights, subject to jurisdiction, patent-term adjustment, patent-term extension and claim validity.
A precise single expiration date cannot be assigned to the entire IPI-549 estate because protection depends on the individual patent, claim scope and country. The practical patent position is:
| Protection category |
Relevance |
| Composition of matter |
Core protection for eganelisib and related PI3K-gamma inhibitors |
| Pharmaceutical compositions |
Protection for formulations and dosage forms |
| Combination therapy |
Potential coverage for use with checkpoint inhibitors or chemotherapy |
| Method of treatment |
Indication-specific protection in solid tumors |
| Manufacturing processes |
Potential barrier to independent synthesis |
| Regulatory exclusivity |
None currently, because no FDA approval exists |
No Orange Book-listed IPI-549 patents exist because the product has no approved FDA reference product. Paragraph IV litigation therefore cannot begin under the Hatch-Waxman framework unless IPI-549 is first approved and listed.
Patent risk remains more relevant to a potential licensee than to generic manufacturers. A new sponsor would need to determine whether composition claims remain enforceable, whether formulation or combination claims can support a future product, and whether the clinical program can generate new patent-term value through later-filed use patents.
Are there Paragraph IV challenges or patent lawsuits involving IPI-549?
No public Paragraph IV challenge has been reported for IPI-549. No established Abbreviated New Drug Application pathway exists because there is no approved reference product.
There is also no widely reported patent litigation involving a generic manufacturer challenging IPI-549 patents. Any historical corporate disputes involving development rights or licensing would be separate from Hatch-Waxman litigation and would not create a generic launch framework.
The lack of litigation is commercial rather than favorable. It reflects the absence of an approved product and a viable generic market.
Does IPI-549 face biosimilar risk?
IPI-549 is a small-molecule drug, not a biologic. Biosimilar regulation under the Biologics Price Competition and Innovation Act does not apply. If IPI-549 is approved, competition would arise through an ANDA or, depending on the product and regulatory strategy, a 505(b)(2) application.
The main post-approval risks would be:
- Paragraph IV patent challenges
- 505(b)(2) development using published clinical data
- Follow-on products with alternative formulations
- Competing PI3K or immuno-oncology mechanisms
- Off-label substitution pressure only if payer and clinical adoption support it
Which companies are competing with IPI-549?
IPI-549 competes less with another PI3K-gamma drug than with multiple immuno-oncology approaches.
| Competitive category |
Representative products or companies |
Competitive effect |
| PD-1 and PD-L1 inhibitors |
Merck, Bristol Myers Squibb, Roche |
Establish combination and first-line standards |
| Antibody-drug conjugates |
Gilead, AstraZeneca, Daiichi Sankyo, ImmunoGen assets |
Reduce demand for broad immunomodulatory combinations |
| PI3K pathway inhibitors |
Novartis, Bayer, Gilead, Secura Bio |
Validate pathway but create safety and differentiation concerns |
| Tumor-microenvironment agents |
Multiple private and public biotechnology companies |
Compete for the same immunosuppressive biology |
| Cellular and bispecific therapies |
Large oncology companies and emerging biotechs |
Increase treatment alternatives in advanced disease |
IPI-549 would require a clearly superior efficacy or tolerability profile to displace established checkpoint inhibitor and antibody-drug conjugate regimens.
What is the commercial market projection for IPI-549?
IPI-549 has no current product revenue. Its commercial value is best modeled through probability-adjusted scenarios rather than a conventional launch forecast.
Base case: no commercial launch
The base case is continued non-commercial status through the medium term. Under this scenario:
- Revenue remains $0.
- No sales force or manufacturing network is built.
- The asset has value mainly as a licensing or acquisition option.
- Patent value declines as core terms approach expiration.
- A new sponsor must fund clinical redevelopment.
Rescue-development case
If a partner restarts development in a biomarker-selected population, a niche launch could produce peak global sales of approximately $100 million to $300 million. This range assumes:
- One approved indication
- Use in combination with a checkpoint inhibitor
- A restricted patient population
- Annual net pricing roughly comparable with specialty oncology products
- Limited uptake because of competing agents
Successful differentiated-combination case
A stronger outcome would require a reproducible survival benefit, a validated biomarker and a manageable safety profile. Under that scenario, peak sales could reach approximately $500 million to $1 billion, but this would require a new pivotal program and several years of development. The probability of this outcome is materially lower than the no-launch scenario based on the disclosed clinical trajectory.
| Scenario |
Approximate peak sales |
Key requirement |
| No launch |
$0 |
Program remains inactive |
| Niche relaunch |
$100 million-$300 million |
Partnered development in a selected population |
| Broad oncology success |
$500 million-$1 billion |
Positive pivotal data and differentiated survival benefit |
These estimates are directional commercial scenarios, not reported company guidance. The most important valuation variable is not the theoretical size of the TNBC or RCC market. It is whether PI3K-gamma inhibition can produce a clinically validated benefit that is distinct from existing immuno-oncology combinations.
What licensing deals affect IPI-549?
Infinity has historically used partnerships to advance IPI-549 and related oncology programs. Takeda was previously associated with the program through a strategic collaboration, but the asset did not progress to commercialization under that relationship.
The current commercial question is whether Infinity or its successor can secure a new partner. A potential transaction would likely be structured around:
- Low upfront consideration
- Development and regulatory milestones
- Regional rights
- Option-based financing
- Access to historical clinical data
- New studies in biomarker-defined solid tumors
The absence of an approved product and the stalled late-stage path would weigh heavily on upfront value. Any meaningful deal would probably depend on a partner identifying a new biological rationale or combination strategy.
How strong is the patent estate for IPI-549?
The estate has strategic value but limited standalone commercial strength. Composition-of-matter protection is the most important category, while method-of-use and combination claims could become more relevant if a new indication is identified.
Patent strength is reduced by four factors:
- No approved product currently supports Orange Book enforcement.
- Clinical development has not established a durable commercial indication.
- Later-filed use patents would expire later but would depend on new clinical data.
- Competitors may avoid the claims through different PI3K-gamma chemotypes or alternative mechanisms.
The estate is therefore stronger as an asset supporting optionality than as a current barrier to market entry.
Key Takeaways
- IPI-549, or eganelisib, is an oral selective PI3K-gamma inhibitor from Infinity Pharmaceuticals.
- The candidate has no FDA approval, no Orange Book listing and no commercial revenue.
- MARIO-3 generated early response signals but did not establish a durable registrational path.
- No Paragraph IV challenge, biosimilar pathway or active generic litigation has been reported.
- Patent protection is expected to extend into the early 2030s for certain rights, but expiration varies by patent and jurisdiction.
- The base commercial forecast is $0 without a development restart.
- A partnered niche launch could support peak sales of $100 million to $300 million.
- Sales above $500 million would require a validated biomarker, positive pivotal data and a clear advantage over checkpoint inhibitors and antibody-drug conjugates.
FAQs
Is IPI-549 still in clinical development?
The publicly disclosed clinical program is not advancing toward an imminent approval. A new sponsor would likely need to restart or redesign development.
What is the generic name of IPI-549?
The nonproprietary name is eganelisib.
Does IPI-549 have an FDA approval date?
No. Eganelisib has no FDA approval date and no approved label.
Is IPI-549 a PI3K inhibitor like alpelisib?
Yes, but it is mechanistically distinct. IPI-549 selectively targets PI3K-gamma, whereas alpelisib primarily targets PI3K-alpha.
Can a generic company file an ANDA for IPI-549?
Not currently through the ordinary commercial pathway because no FDA-approved IPI-549 reference product exists. An ANDA strategy would become relevant only after approval of a reference product and listing of applicable patents.
References
-
ClinicalTrials.gov. (2024). Study of IPI-549 in combination with nivolumab in patients with advanced solid tumors: MARIO-1. U.S. National Library of Medicine.
-
ClinicalTrials.gov. (2024). Study of IPI-549 in combination with atezolizumab and nab-paclitaxel in patients with metastatic triple-negative breast cancer: MARIO-3. U.S. National Library of Medicine.
-
Infinity Pharmaceuticals, Inc. (2022). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024). Fast Track designation and development programs. FDA.
-
Infinity Pharmaceuticals, Inc. (2021). Corporate presentation and clinical development update for eganelisib. Infinity Pharmaceuticals.